Ergoteles’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Ergoteles’s Portfolio INFI Stock Details INFI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-696,506	Closed	-$147K	–	965
2023 Q2	$147K	Hold	696,506	–	–	0.01%	888
2023 Q1	$111K	Buy	696,506 +626,846	+900%	+$278K	﹤0.01%	1091
2022 Q4	$38.7K	Sell	69,660 -338,754	-83%	-$288K	﹤0.01%	1317
2022 Q3	$486K	Sell	408,414 -11,238	-3%	-$12.1K	0.02%	774
2022 Q2	$265K	Buy	+419,652	New	+$322K	0.01%	1174

Other funds holding INFI

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Ergoteles's INFI Position: Q3 2023 in Review

Ergoteles sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q3 2023, closing a stake of 696,506 shares — an estimated $147K sold.

Ergoteles first reported a position in INFI in Q2 2022 and held it in 5 quarters. The position peaked at $486K in Q3 2022. 3 funds tracked by Wall St. Rank hold INFI as of Q3 2023.

Ergoteles reported no remaining Infinity Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
Ergoteles sold 696,506 Infinity Pharmaceuticals, Inc. shares in Q3 2023, an estimated $147K.
Ergoteles first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2022 and held it in 5 quarters.
Ergoteles's Infinity Pharmaceuticals, Inc. position peaked at $486K in Q3 2022.
3 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.